This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Bardet - Biedl syndrome

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • characterised by retinal dystrophy, hypogonadism, reduced IQ, obesity (+/- polydactyly) plus renal abnormalities (calcyceal cysts or diverticula, calyceal blunting or clubbing, fetal lobulation)
  • this syndrome does not have neurological symptoms (spastic paraplegia) - this differentiates it from Laurence-Moon-Biedl syndrome
  • recessive inheritance
    • genetic locus:
      • BBS1 has no linkage to chromosome 16
      • BBS2 is mapped to markers on chromosome 16.
  • epidemiology
    • incidence 1: 160,000; in Newfoundland the incidence is much higher at 1: 16,000

NICE guidance setmelanotide in Bardet-Biedel syndrome

  • recommends setmelanotide as an option for treating obesity and hyperphagia in genetically confirmed BBS in people aged ≥ 6 years, only if they are aged between 6 and 17 years when treatment starts
  • can carry on having setmelanotide as adults until they need to stop

Main contributor for Bardet - Biedl syndrome section: Thomas Waterfield (October 2007).

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.